Avid Bioservices Acquisition by GHO Capital and Ampersand Completed
Deal News | Feb 05, 2025 | Ampersand Capital Partners
The acquisition of Avid Bioservices, a biologics Contract Development and Manufacturing Organisation (CDMO), by GHO Capital Partners LLP and Ampersand Capital Partners has been successfully closed, marking a significant transition for Avid. Initially agreed upon on November 7, 2024, the all-cash transaction was valued at approximately $1.1 billion. With substantial growth in recent years, Avid offers lifecycle capabilities from concept to commercial supply, supported by its advanced facilities and expertise in bioprocess optimization and regulatory compliance. Both GHO and Ampersand bring extensive experience in the life sciences and healthcare sectors, poised to drive Avid through the next growth phase. GHO plans to enhance Avid's technological capabilities and transatlantic reach, while Ampersand emphasizes innovation and value delivery. The transaction underscores a strategic move within the healthcare investment landscape, supported by financial, legal, and commercial advisors including William Blair, Ropes & Gray, ClearView Healthcare Partners, and Alvarez & Marsal.
Sectors
- Biotechnology
- Healthcare
- Private Equity
Geography
- United States – Avid Bioservices is based in the USA, and Ampersand Capital Partners has offices in Boston, MA.
- United Kingdom – GHO Capital Partners, involved in this transaction, is based in London, UK.
Industry
- Biotechnology – Avid Bioservices operates as a biologics CDMO serving biotechnology and pharmaceutical companies.
- Healthcare – GHO Capital and Ampersand Capital Partners specialize in healthcare investments, influencing this sector with their investment in Avid.
- Private Equity – Ampersand Capital is a private equity firm focused on the healthcare sector, and the article discusses a significant investment made by them in Avid Bioservices.
Financials
- $1.1 billion – The all-cash transaction value for the acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Avid Bioservices | Target | Company | A biologics CDMO focused on the development and manufacturing of biologics, serving the biotechnology and pharmaceutical industries. |
| GHO Capital Partners LLP | Bidding Company | Company | A specialist healthcare investment advisor from London with a focus on global healthcare. |
| Ampersand Capital Partners | Bidding Company | Company | A middle-market private equity firm investing in the healthcare sector, with a focus on growth-oriented investments. |
| William Blair | Financial Advisor | Company | Served as buy-side financial advisers for the acquisition. |
| Ropes & Gray | Legal Advisor | Company | Provided legal counsel for GHO and Ampersand in this transaction. |
| ClearView Healthcare Partners | Commercial Advisor | Company | Served as commercial advisor for the acquisition. |
| Alvarez & Marsal | Financial Advisor | Company | Provided financial advisory services to GHO and Ampersand. |